Vaughan H, Zamboni C, Radant N, Bhardwaj P, Revai Lechtich E, Hassan L, et al. Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Mol Ther Oncolytics. 2021;21:377-388 pubmed publisher

Malik Y, Sheikh M, Xing Z, Guo Z, Zhu X, Tian H, et al. Polylysine-modified polyethylenimine polymer can generate genetically engineered mesenchymal stem cells for combinational suicidal gene therapy in glioblastoma. Acta Biomater. 2018;80:144-153 pubmed publisher

Zhou X, Liu Z, Wang H, Liu X, Zhou Z, Tang J, et al. SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy. J Drug Target. 2018;:1-9 pubmed publisher

Rinaldi L, Folliero V, Palomba L, Zannella C, Isticato R, Di Francia R, et al. Sonoporation by microbubbles as gene therapy approach against liver cancer. Oncotarget. 2018;9:32182-32190 pubmed publisher

Han J, Hwang H, Na K. TRAIL-secreting human mesenchymal stem cells engineered by a non-viral vector and photochemical internalization for pancreatic cancer gene therapy. Biomaterials. 2018;182:259-268 pubmed publisher

Tanrikulu B, Ziyal I, Bayri Y. In Vitro Effects of Mesenchymal Stem Cells and Various Agents on Apoptosis of Glioblastoma Cells. Turk Neurosurg. 2019;29:26-32 pubmed publisher

Tzeng S, Wilson D, Hansen S, Quinones Hinojosa A, Green J. Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng Transl Med. 2016;1:149-159 pubmed publisher

El Sharkawi F, Ewais S, Fahmy R, Rashed L. PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma. J Drug Target. 2017;25:513-522 pubmed publisher

Han Z, Lee S, Je S, Eom C, Choi H, Song J, et al. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. Apoptosis. 2016;21:351-64 pubmed publisher

Hartung F, Stuhmer W, Pardo L. Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Mol Cancer. 2011;10:109 pubmed publisher

Kagawa S, He C, Gu J, Koch P, Rha S, Roth J, et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 2001;61:3330-8 pubmed